{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:31:44Z","timestamp":1782448304027,"version":"3.54.5"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA015083"],"award-info":[{"award-number":["P30CA015083"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005968","name":"Leukemia Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014535","name":"Mayo Clinic Center for Individualized Medicine","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014535","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Constitutively activated B cell receptor (BCR) signaling is a primary biological feature of chronic lymphocytic leukemia (CLL). The biological events controlled by BCR signaling in CLL are not fully understood and need investigation. Here, by analysis of the chromatin states and gene expression profiles of CLL B cells from patients before and after Bruton\u2019s tyrosine kinase inhibitor (BTKi) ibrutinib treatment, we show that BTKi treatment leads to a decreased expression of APOBEC3 family genes by regulating the activity of their enhancers. BTKi treatment reduces enrichment of enhancer marks (H3K4me1 and H3K27ac) and chromatin accessibility at putative APOBEC3 enhancers. CRISPR-Cas9 directed deletion or inhibition of the putative APOBEC3 enhancers leads to reduced APOBEC3 expression. We further find that transcription factor NFATc1 couples BCR signaling with the APOBEC3 enhancer activity to control APOBEC3 expression. We also find that enhancer-regulated APOBEC3 expression contributes to replication stress in malignant B cells. In total we demonstrate a novel mechanism for BTKi suppression of APOBEC3 expression via direct enhancer regulation in an NFATc1-dependent manner, implicating BCR signaling as a potential regulator of leukemic genomic instability.<\/jats:p>","DOI":"10.1038\/s41408-022-00690-w","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T08:20:34Z","timestamp":1656663634000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8243-7251","authenticated-orcid":false,"given":"Zhiquan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0756-2922","authenticated-orcid":false,"given":"Huihuang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin C.","family":"Boysen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charla R.","family":"Secreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee C.","family":"Tschumper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dania","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7157-603X","authenticated-orcid":false,"given":"Jian","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyun","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanhe","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane F.","family":"Jelinek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5173-4712","authenticated-orcid":false,"given":"Susan L.","family":"Slager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3221-7314","authenticated-orcid":false,"given":"Sameer A.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Braggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5951-5055","authenticated-orcid":false,"given":"Neil E.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,1]]},"reference":[{"key":"690_CR1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/nrc.2017.121","volume":"18","author":"JA Burger","year":"2018","unstructured":"Burger JA, Wiestner A. Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer. 2018;18:148\u201367.","journal-title":"Nat Rev Cancer"},{"key":"690_CR2","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.it.2013.07.002","volume":"34","author":"JA Burger","year":"2013","unstructured":"Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 2013;34:592\u2013601.","journal-title":"Trends Immunol"},{"key":"690_CR3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri2491","volume":"9","author":"S Herzog","year":"2009","unstructured":"Herzog S, Reth M, Jumaa H. Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling. Nat Rev Immunol. 2009;9:195\u2013205.","journal-title":"Nat Rev Immunol"},{"key":"690_CR4","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N. Engl J Med. 2015;373:2425\u201337.","journal-title":"N. Engl J Med"},{"key":"690_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O\u2019Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N. Engl J Med. 2014;371:213\u201323.","journal-title":"N. Engl J Med"},{"key":"690_CR6","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","volume":"395","author":"JP Sharman","year":"2020","unstructured":"Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395:1278\u201391.","journal-title":"Lancet"},{"key":"690_CR7","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/nbt1010-1033","volume":"28","author":"HP Mohammad","year":"2010","unstructured":"Mohammad HP, Baylin SB. Linking cell signaling and the epigenetic machinery. Nat Biotechnol. 2010;28:1033\u20138.","journal-title":"Nat Biotechnol"},{"key":"690_CR8","doi-asserted-by":"publisher","first-page":"8652748","DOI":"10.1155\/2016\/8652748","volume":"2016","author":"L Fagnocchi","year":"2016","unstructured":"Fagnocchi L, Mazzoleni S, Zippo A. Integration of signaling pathways with the epigenetic machinery in the maintenance of stem cells. Stem Cells Int. 2016;2016:8652748.","journal-title":"Stem Cells Int"},{"key":"690_CR9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/ng1089","volume":"33","author":"R Jaenisch","year":"2003","unstructured":"Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet. 2003;33:245\u201354.","journal-title":"Nat Genet"},{"key":"690_CR10","doi-asserted-by":"publisher","first-page":"e8339","DOI":"10.15252\/msb.20188339","volume":"15","author":"JP Mallm","year":"2019","unstructured":"Mallm JP, Iskar M, Ishaque N, Klett LC, Kugler SJ, Muino JM, et al. Linking aberrant chromatin features in chronic lymphocytic leukemia to transcription factor networks. Mol Syst Biol. 2019;15:e8339.","journal-title":"Mol Syst Biol"},{"key":"690_CR11","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41591-018-0028-4","volume":"24","author":"R Beekman","year":"2018","unstructured":"Beekman R, Chapaprieta V, Russinol N, Vilarrasa-Blasi R, Verdaguer-Dot N, Martens JHA, et al. The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia. Nat Med. 2018;24:868\u201380.","journal-title":"Nat Med"},{"key":"690_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14081-6","volume":"11","author":"AF Rendeiro","year":"2020","unstructured":"Rendeiro AF, Krausgruber T, Fortelny N, Zhao F, Penz T, Farlik M, et al. Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL. Nat Commun. 2020;11:577.","journal-title":"Nat Commun"},{"key":"690_CR13","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nrg3207","volume":"13","author":"F Spitz","year":"2012","unstructured":"Spitz F, Furlong EEM. Transcription factors: from enhancer binding to developmental control. Nat Rev Genet. 2012;13:613\u201326.","journal-title":"Nat Rev Genet"},{"key":"690_CR14","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.4049\/jimmunol.1501504","volume":"195","author":"S Stavrou","year":"2015","unstructured":"Stavrou S, Ross SR. APOBEC3 proteins in viral immunity. J Immunol. 2015;195:4565\u201370.","journal-title":"J Immunol"},{"key":"690_CR15","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1158\/2159-8290.CD-20-0725","volume":"11","author":"S Venkatesan","year":"2021","unstructured":"Venkatesan S, Angelova M, Puttick C, Zhai H, Caswell DR, Lu W-T, et al. Induction of APOBEC3 exacerbates DNA replication stress and chromosomal instability in early breast and lung cancer evolution. Cancer Discov. 2021;11:2456\u201373.","journal-title":"Cancer Discov"},{"key":"690_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7997","volume":"6","author":"BA Walker","year":"2015","unstructured":"Walker BA, Wardell CP, Murison A, Boyle EM, Begum DB, Dahir NM, et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun. 2015;6:6997.","journal-title":"Nat Commun"},{"key":"690_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jncc.2020.12.003","volume":"1","author":"Z Wang","year":"2021","unstructured":"Wang Z, Wu R, Nie Q, Bouchonville KJ, Diasio RB, Offer SM. Chromatin assembly factor 1 suppresses epigenetic reprogramming toward adaptive drug resistance. J Natl Cancer Cent. 2021;1:15\u201322.","journal-title":"J Natl Cancer Cent"},{"key":"690_CR18","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/nmeth.4396","volume":"14","author":"MR Corces","year":"2017","unstructured":"Corces MR, Trevino AE, Hamilton EG, Greenside PG, Sinnott-Armstrong NA, Vesuna S, et al. An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues. Nat Methods. 2017;14:959\u201362.","journal-title":"Nat Methods"},{"key":"690_CR19","doi-asserted-by":"publisher","first-page":"650.","DOI":"10.3390\/cancers12030650","volume":"12","author":"S Roy Chowdhury","year":"2020","unstructured":"Roy Chowdhury S, Bouchard EDJ, Saleh R, Nugent Z, Peltier C, Mejia E, et al. Mitochondrial respiration correlates with prognostic markers in chronic lymphocytic leukemia and is normalized by ibrutinib treatment. Cancers. 2020;12:650.","journal-title":"Cancers"},{"key":"690_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.virol.2015.03.012","volume":"479-80:","author":"RS Harris","year":"2015","unstructured":"Harris RS, Dudley JP. APOBECs and virus restriction. Virology. 2015;479-80::131\u201345.","journal-title":"Virology"},{"key":"690_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.chembiol.2017.10.007","volume":"25","author":"ME Olson","year":"2018","unstructured":"Olson ME, Harris RS, Harki DA. APOBEC enzymes as targets for virus and cancer therapy. Cell Chem Biol. 2018;25:36\u201349.","journal-title":"Cell Chem Biol"},{"key":"690_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1182\/blood.2019003715","volume":"136","author":"C Sun","year":"2020","unstructured":"Sun C, Nierman P, Kendall EK, Cheung J, Gulrajani M, Herman SEM, et al. Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib. Blood. 2020;136:93\u2013105.","journal-title":"Blood"},{"key":"690_CR23","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1182\/blood-2018-09-876292","volume":"133","author":"PE Morande","year":"2019","unstructured":"Morande PE, Sivina M, Uriepero A, Seija N, Berca C, Fresia P, et al. Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia. Blood. 2019;133:2056\u201368.","journal-title":"Blood"},{"key":"690_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09645-5","volume":"10","author":"A Pastore","year":"2019","unstructured":"Pastore A, Gaiti F, Lu SX, Brand RM, Kulm S, Chaligne R, et al. Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL. Nat Commun. 2019;10:1874.","journal-title":"Nat Commun"},{"key":"690_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09982-5","volume":"10","author":"HS Kaya-Okur","year":"2019","unstructured":"Kaya-Okur HS, Wu SJ, Codomo CA, Pledger ES, Bryson TD, Henikoff JG, et al. CUT&Tag for efficient epigenomic profiling of small samples and single cells. Nat Commun. 2019;10:1930.","journal-title":"Nat Commun"},{"key":"690_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-019-0142-2","volume":"8","author":"KB Holmes","year":"2019","unstructured":"Holmes KB, Sadreev II, Rawstron AC, Munir T, Westhead DR, Hillmen P, et al. Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells. Oncogenesis. 2019;8:32.","journal-title":"Oncogenesis"},{"key":"690_CR27","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1126\/science.1181369","volume":"326","author":"E Lieberman-Aiden","year":"2009","unstructured":"Lieberman-Aiden E, van Berkum NL, Williams L, Imakaev M, Ragoczy T, Telling A, et al. Comprehensive mapping of long-range interactions reveals folding principles of the human genome. Science. 2009;326:289\u201393.","journal-title":"Science"},{"key":"690_CR28","first-page":"75","volume":"1","author":"T Hussain","year":"2012","unstructured":"Hussain T, Mulherkar R. Lymphoblastoid cell lines: a continuous in vitro source of cells to study carcinogen sensitivity and DNA repair. Int J Mol Cell Med. 2012;1:75\u201387.","journal-title":"Int J Mol Cell Med"},{"key":"690_CR29","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.ccell.2018.11.001","volume":"34","author":"CJ Ott","year":"2018","unstructured":"Ott CJ, Federation AJ, Schwartz LS, Kasar S, Klitgaard JL, Lenci R, et al. Enhancer architecture and essential core regulatory circuitry of chronic lymphocytic leukemia. Cancer Cell. 2018;34:982\u201395.","journal-title":"Cancer Cell"},{"key":"690_CR30","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41588-021-00838-7","volume":"53","author":"ML Leibowitz","year":"2021","unstructured":"Leibowitz ML, Papathanasiou S, Doerfler PA, Blaine LJ, Sun L, Yao Y, et al. Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing. Nat Genet. 2021;53:895\u2013905.","journal-title":"Nat Genet"},{"key":"690_CR31","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/j.cell.2021.03.025","volume":"184","author":"JK Nu\u00a4ez","year":"2021","unstructured":"Nu\u00a4ez JK, Chen J, Pommier GC, Cogan JZ, Replogle JM, Adriaens C, et al. Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing. Cell. 2021;184:2503\u201319.e17.","journal-title":"Cell"},{"key":"690_CR32","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41592-018-0048-5","volume":"15","author":"NC Yeo","year":"2018","unstructured":"Yeo NC, Chavez A, Lance-Byrne A, Chan Y, Menn D, Milanova D, et al. An enhanced CRISPR repressor for targeted mammalian gene regulation. Nat Methods. 2018;15:611\u20136.","journal-title":"Nat Methods"},{"key":"690_CR33","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.molcel.2020.12.047","volume":"81","author":"HF Thomas","year":"2021","unstructured":"Thomas HF, Kotova E, Jayaram S, Pilz A, Romeike M, Lackner A, et al. Temporal dissection of an enhancer cluster reveals distinct temporal and functional contributions of individual elements. Mol Cell. 2021;81:969\u2013982.","journal-title":"Mol Cell"},{"key":"690_CR34","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1146\/annurev-genet-030220-015007","volume":"54","author":"KS Zaret","year":"2020","unstructured":"Zaret KS. Pioneer transcription factors initiating gene network changes. Annu Rev Genet. 2020;54:367\u201385.","journal-title":"Annu Rev Genet"},{"key":"690_CR35","doi-asserted-by":"publisher","first-page":"651057.","DOI":"10.3389\/fonc.2021.651057","volume":"11","author":"I Sana","year":"2021","unstructured":"Sana I, Mantione ME, Angelillo P, Muzio M. Role of NFAT in chronic lymphocytic leukemia and other B-cell malignancies. Front Oncol. 2021;11:651057.","journal-title":"Front Oncol"},{"key":"690_CR36","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.4049\/jimmunol.1003050","volume":"186","author":"S Garaud","year":"2011","unstructured":"Garaud S, Morva A, Lemoine S, Hillion S, Bordron A, Pers J-O, et al. CD5 promotes IL-10 production in chronic lymphocytic leukemia B cells through STAT3 and NFAT2 activation. J Immunol. 2011;186:4835\u201344.","journal-title":"J Immunol"},{"key":"690_CR37","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.chom.2014.12.013","volume":"17","author":"H Zhou","year":"2015","unstructured":"Zhou H, Schmidt SC, Jiang S, Willox B, Bernhardt K, Liang J, et al. Epstein-Barr virus oncoprotein super-enhancers control B cell growth. Cell Host Microbe. 2015;17:205\u201316.","journal-title":"Cell Host Microbe"},{"key":"690_CR38","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1074\/jbc.M110.154377","volume":"286","author":"MA Farrow","year":"2011","unstructured":"Farrow MA, Kim EY, Wolinsky SM, Sheehy AM. NFAT and IRF proteins regulate transcription of the anti-HIV gene, APOBEC3G. J Biol Chem. 2011;286:2567\u201377.","journal-title":"J Biol Chem"},{"key":"690_CR39","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.jmb.2013.10.033","volume":"426","author":"BA Desimmie","year":"2014","unstructured":"Desimmie BA, Delviks-Frankenberrry KA, Burdick RC, Qi D, Izumi T, Pathak VK. Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. J Mol Biol. 2014;426:1220\u201345.","journal-title":"J Mol Biol"},{"key":"690_CR40","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/0167-5699(92)90111-J","volume":"13","author":"SL Schreiber","year":"1992","unstructured":"Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today. 1992;13:136\u201342.","journal-title":"Immunol Today"},{"key":"690_CR41","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.devcel.2006.04.006","volume":"10","author":"MM Winslow","year":"2006","unstructured":"Winslow MM, Pan M, Starbuck M, Gallo EM, Deng L, Karsenty G, et al. Calcineurin\/NFAT signaling in osteoblasts regulates bone mass. Dev Cell. 2006;10:771\u201382.","journal-title":"Dev Cell"},{"key":"690_CR42","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1073\/pnas.1720355115","volume":"115","author":"D Gupta","year":"2018","unstructured":"Gupta D, Lin B, Cowan A, Heinen CD. ATR-Chk1 activation mitigates replication stress caused by mismatch repair-dependent processing of DNA damage. Proc Natl Acad Sci USA. 2018;115:1523\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"690_CR43","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/ncb2201","volume":"13","author":"C Lukas","year":"2011","unstructured":"Lukas C, Savic V, Bekker-Jensen S, Doil C, Neumann B, S\u00f8lvh\u00f8j Pedersen R, et al. 53BP1 nuclear bodies form around DNA lesions generated by mitotic transmission of chromosomes under replication stress. Nat Cell Biol. 2011;13:243\u201353.","journal-title":"Nat Cell Biol"},{"key":"690_CR44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/cr.2014.147","volume":"25","author":"A Mar\u00e9chal","year":"2015","unstructured":"Mar\u00e9chal A, Zou L. RPA-coated single-stranded DNA as a platform for post-translational modifications in the DNA damage response. Cell Res. 2015;25:9\u201323.","journal-title":"Cell Res"},{"key":"690_CR45","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.cell.2017.07.043","volume":"170","author":"S Hamperl","year":"2017","unstructured":"Hamperl S, Bocek MJ, Saldivar JC, Swigut T, Cimprich KA. Transcription-replication conflict orientation modulates R-loop levels and activates distinct DNA damage responses. Cell. 2017;170:774\u2013786.","journal-title":"Cell"},{"key":"690_CR46","doi-asserted-by":"publisher","first-page":"e1002247","DOI":"10.1371\/journal.pgen.1002247","volume":"7","author":"E Outwin","year":"2011","unstructured":"Outwin E, Carpenter G, Bi W, Withers MA, Lupski JR, O\u2019Driscoll M. Increased RPA1 gene dosage affects genomic stability potentially contributing to 17p13.3 duplication syndrome. PLoS Genet. 2011;7:e1002247.","journal-title":"PLoS Genet"},{"key":"690_CR47","doi-asserted-by":"publisher","first-page":"9889","DOI":"10.1021\/acs.jmedchem.8b01187","volume":"61","author":"KM Foote","year":"2018","unstructured":"Foote KM, Nissink JWM, McGuire T, Turner P, Guichard S, Yates JWT, et al. Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent. J Medicinal Chem. 2018;61:9889\u2013907.","journal-title":"J Medicinal Chem"},{"key":"690_CR48","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41586-019-1732-z","volume":"575","author":"WB Hamilton","year":"2019","unstructured":"Hamilton WB, Mosesson Y, Monteiro RS, Emdal KB, Knudsen TE, Francavilla C, et al. Dynamic lineage priming is driven via direct enhancer regulation by ERK. Nature. 2019;575:355\u201360.","journal-title":"Nature"},{"key":"690_CR49","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41556-018-0086-3","volume":"20","author":"LWS Finley","year":"2018","unstructured":"Finley LWS, Vardhana SA, Carey BW, Alonso-Curbelo D, Koche R, Chen Y, et al. Pluripotency transcription factors and Tet1\/2 maintain Brd4-independent stem cell identity. Nat Cell Biol. 2018;20:565\u201374.","journal-title":"Nat Cell Biol"},{"key":"690_CR50","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41591-018-0158-8","volume":"24","author":"F Zanconato","year":"2018","unstructured":"Zanconato F, Battilana G, Forcato M, Filippi L, Azzolin L, Manfrin A, et al. Transcriptional addiction in cancer cells is mediated by YAP\/TAZ through BRD4. Nat Med. 2018;24:1599\u2013610.","journal-title":"Nat Med"},{"key":"690_CR51","doi-asserted-by":"publisher","first-page":"e02313","DOI":"10.7554\/eLife.02313","volume":"3","author":"RW Serra","year":"2014","unstructured":"Serra RW, Fang M, Park SM, Hutchinson L, Green MR. A KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotype. eLife. 2014;3:e02313.","journal-title":"eLife"},{"key":"690_CR52","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1182\/blood-2011-12-397158","volume":"120","author":"C Le Roy","year":"2012","unstructured":"Le Roy C, Deglesne PA, Chevallier N, Beitar T, Eclache V, Quettier M, et al. The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia. Blood. 2012;120:356\u201365.","journal-title":"Blood"},{"key":"690_CR53","doi-asserted-by":"publisher","first-page":"24172","DOI":"10.1074\/jbc.M116.739326","volume":"291","author":"CH Gabriel","year":"2016","unstructured":"Gabriel CH, Gross F, Karl M, Stephanowitz H, Hennig AF, Weber M, et al. Identification of novel nuclear factor of activated T cell (NFAT)-associated proteins in T cells. J Biol Chem. 2016;291:24172\u201387.","journal-title":"J Biol Chem"},{"key":"690_CR54","first-page":"60","volume":"4","author":"MD Blunt","year":"2015","unstructured":"Blunt MD, Steele AJ. Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia. Leuk Res Rep. 2015;4:60\u201363.","journal-title":"Leuk Res Rep."},{"key":"690_CR55","doi-asserted-by":"crossref","unstructured":"Okkenhaug K, Burger JA. PI3K signaling in normal B cells and chronic lymphocytic leukemia (CLL). In: Kurosaki T, Wienands J, editors. B cell receptor signaling. Cham: Springer International Publishing; 2016. p. 123\u201342.","DOI":"10.1007\/82_2015_484"},{"key":"690_CR56","doi-asserted-by":"publisher","first-page":"14483","DOI":"10.1074\/jbc.272.22.14483","volume":"272","author":"T Jascur","year":"1997","unstructured":"Jascur T, Gilman J, Mustelin T. Involvement of phosphatidylinositol 3-kinase in NFAT activation in T cells. J Biol Chem. 1997;272:14483\u20138.","journal-title":"J Biol Chem"},{"key":"690_CR57","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1080\/10428194.2018.1523401","volume":"60","author":"I Innocenti","year":"2019","unstructured":"Innocenti I, Morelli F, Autore F, Corbingi A, Pasquale R, Sora F, et al. HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis. Leuk Lymphoma. 2019;60:1340\u20132.","journal-title":"Leuk Lymphoma"},{"key":"690_CR58","first-page":"424","volume":"78","author":"P de Jesus Ngoma","year":"2015","unstructured":"de Jesus Ngoma P, Kabamba B, Dahlqvist G, Sempoux C, Lanthier N, Shindano T, et al. Occult HBV reactivation induced by ibrutinib treatment: a case report. Acta Gastroenterol Belg. 2015;78:424\u20136.","journal-title":"Acta Gastroenterol Belg"},{"key":"690_CR59","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nrm.2016.88","volume":"17","author":"T Garc\u00eda-Muse","year":"2016","unstructured":"Garc\u00eda-Muse T, Aguilera A. Transcription\u2013replication conflicts: how they occur and how they are resolved. Nat Rev Mol Cell Biol. 2016;17:553\u201363.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"690_CR60","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/JLB.2AB0218-076RR","volume":"105","author":"DJ M\u00fcller","year":"2019","unstructured":"M\u00fcller DJ, Wirths S, Fuchs AR, M\u00e4rklin M, Heitmann JS, Sturm M, et al. Loss of NFAT2 expression results in the acceleration of clonal evolution in chronic lymphocytic leukemia. J Leukoc Biol. 2019;105:531\u20138.","journal-title":"J Leukoc Biol"},{"key":"690_CR61","doi-asserted-by":"publisher","first-page":"W208","DOI":"10.1093\/nar\/gkaa252","volume":"48","author":"C Leporcq","year":"2020","unstructured":"Leporcq C, Spill Y, Balaramane D, Toussaint C, Weber M, Bardet AF. TFmotifView: a webserver for the visualization of transcription factor motifs in genomic regions. Nucleic Acids Res. 2020;48:W208\u2013W217.","journal-title":"Nucleic Acids Res"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00690-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00690-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00690-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T15:09:43Z","timestamp":1669216183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00690-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":61,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["690"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00690-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.07.27.454050","asserted-by":"object"}]},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,1]]},"assertion":[{"value":"21 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NEK Advisory Board for Abbvie, AstraZeneca, BeiGene, Behring, Cytomx Therapy, Dava Oncology, Janssen, Juno Therapeutics, Oncotracker, Pharmacyclics and Targeted Oncology. DSMC (Data Safety Monitoring Committee) for Agios Pharm, AstraZeneca, BMS\/Celgene, Cytomx Therapeutics, Janssen, Morpho-sys, Rigel. Research funding from Abbvie, Acerta Pharma, Bristol Meyer Squib, Celgene, Genentech, MEI Pharma, Pharmacyclics, Sunesis, TG Therapeutics, and Tolero Pharmaceuticals. SAP: Research funding has been provided to the institution from Pharmacyclics, Janssen, AstraZeneca, TG Therapeutics, Merck, AbbVie, and Ascentage Pharma for clinical studies in which SAP is a principal investigator. SAP has also participated in Advisory Board meetings of Pharmacyclics, AstraZeneca, Genentech, GlaxoSmithKline, Adaptive Health, Adaptive Biotechnologies, and AbbVie (he was not personally compensated for his participation).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}